Halozyme Therapeutics Inc. (HALO)
Analysts Just Upgraded these Five Stocks
Bank of America reiterated its buy rating on Palantir with a price target of $180.
Halozyme Therapeutics, Inc. (HALO) Q2 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO ) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants Helen I. Torley - President, CEO & Director Nicole LaBrosse - Senior VP & CFO Tram Bui - Head of Investor Relations & Corporate Communications Conference Call Participants Adam Ferrari - JPMorgan Chase & Co, Research Division Brendan Mychal Smith - TD Cowen, Research Division Corinne Johnson - Goldman Sachs Group, Inc., Research Division Jason Nicholas Butler - Citizens JMP Securities, LLC, Research Division Michael Gennaro DiFiore - Evercore ISI Institutional Equities, Research Division Mitchell Swaroop Kapoor - H.C.
Compared to Estimates, Halozyme Therapeutics (HALO) Q2 Earnings: A Look at Key Metrics
Although the revenue and EPS for Halozyme Therapeutics (HALO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Surpass Estimates
Halozyme Therapeutics (HALO) came out with quarterly earnings of $1.54 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $0.91 per share a year ago.
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
Halozyme Therapeutics (HALO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Halozyme Therapeutics (HALO) is Poised to Beat Earnings Estimates Again
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade)
Halozyme Therapeutics, Inc.'s ENHANZE technology drives strong near-term growth, but its key patent expires in 2027, raising long-term sustainability concerns. MDASE, once seen as the next growth engine, now appears more like a speculative 'call option' due to patent litigation setbacks and a lack of partnerships. Despite robust revenue and profitability, management's focus on share buybacks over R&D and unclear post-ENHANZE strategy is worrying.
Why Halozyme Therapeutics (HALO) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Halozyme Therapeutics (HALO) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
